Market capitalization | $151.16m |
Enterprise Value | $145.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 30.34 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-10.76m |
Free Cash Flow (TTM) Free Cash Flow | $-7.57m |
Cash position | $5.82m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Greenwich LifeSciences Inc:
1 Analyst has issued a forecast Greenwich LifeSciences Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -11 -11 |
15%
15%
|
EBIT (Operating Income) EBIT | -11 -11 |
15%
15%
|
Net Profit | -11 -11 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Head office | United States |
CEO | Snehal Patel |
Employees | 7 |
Founded | 2006 |
Website | www.greenwichlifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.